OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15
Rafael Alonso Fernández, Jessica Encinas, Laetitia Pierre-Louis, et al.
Blood Advances (2022) Vol. 7, Iss. 1, pp. 9-19
Open Access | Times Cited: 15
Rafael Alonso Fernández, Jessica Encinas, Laetitia Pierre-Louis, et al.
Blood Advances (2022) Vol. 7, Iss. 1, pp. 9-19
Open Access | Times Cited: 15
Showing 15 citing articles:
Research progress of interleukin-15 in cancer immunotherapy
Menghan Cai, Xuan Huang, Xiting Huang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 35
Menghan Cai, Xuan Huang, Xiting Huang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 35
Engineering cytokines for cancer immunotherapy: a systematic review
Yong Fu, Renhong Tang, Xiaofeng Zhao
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 20
Yong Fu, Renhong Tang, Xiaofeng Zhao
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 20
The role of interleukin-15 in the development and treatment of hematological malignancies
Paola Del Sindaco, Hritisha Pandey, Colleen Isabelle, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 17
Paola Del Sindaco, Hritisha Pandey, Colleen Isabelle, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 17
Facts and Hopes on Chimeric Cytokine Agents for Cancer Immunotherapy
Zhenhua Ren, Xuhao Zhang, Yang–Xin Fu
Clinical Cancer Research (2024) Vol. 30, Iss. 10, pp. 2025-2038
Closed Access | Times Cited: 6
Zhenhua Ren, Xuhao Zhang, Yang–Xin Fu
Clinical Cancer Research (2024) Vol. 30, Iss. 10, pp. 2025-2038
Closed Access | Times Cited: 6
Phenotypic Heterogeneity of Dysfunctional Natural Killer Cells During Chronic Infection or Cancer
Kévin Pouxvielh, Marie Marotel, Noëmi Rousseaux, et al.
Springer eBooks (2025), pp. 1-31
Closed Access
Kévin Pouxvielh, Marie Marotel, Noëmi Rousseaux, et al.
Springer eBooks (2025), pp. 1-31
Closed Access
Cytokine-based immunotherapy in hematolymphoid malignancies
Mário Sousa‐Pimenta, Nuno R. dos Santos
International review of cell and molecular biology (2025)
Closed Access
Mário Sousa‐Pimenta, Nuno R. dos Santos
International review of cell and molecular biology (2025)
Closed Access
Targeting γc family cytokines with biologics: current status and future prospects
Fabian Bick, Christophe Blanchetot, Bart N. Lambrecht, et al.
mAbs (2025) Vol. 17, Iss. 1
Open Access
Fabian Bick, Christophe Blanchetot, Bart N. Lambrecht, et al.
mAbs (2025) Vol. 17, Iss. 1
Open Access
Drug delivery methods for cancer immunotherapy
Edgar Pérez‐Herrero, Olivia L. Lanier, Neha Krishnan, et al.
Drug Delivery and Translational Research (2023) Vol. 14, Iss. 1, pp. 30-61
Open Access | Times Cited: 14
Edgar Pérez‐Herrero, Olivia L. Lanier, Neha Krishnan, et al.
Drug Delivery and Translational Research (2023) Vol. 14, Iss. 1, pp. 30-61
Open Access | Times Cited: 14
Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling
Rahul Banerjee, Kara I. Cicero, Sarah S. Lee, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 11
Rahul Banerjee, Kara I. Cicero, Sarah S. Lee, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 11
Natural killer cells affect the natural course, drug resistance, and prognosis of multiple myeloma
Li Zhang, Xiaohuan Peng, Tao Ma, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 2
Li Zhang, Xiaohuan Peng, Tao Ma, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 2
Revitalizing Cytokine‐Based Cancer Immunotherapy through Advanced Delivery Systems
Pengwen Chen, West Kristian D. Paraiso, Horacio Cabral
Macromolecular Bioscience (2023) Vol. 23, Iss. 12
Closed Access | Times Cited: 5
Pengwen Chen, West Kristian D. Paraiso, Horacio Cabral
Macromolecular Bioscience (2023) Vol. 23, Iss. 12
Closed Access | Times Cited: 5
Translational PK/PD and the first-in-human dose selection of a PD1/IL15: an engineered recombinant targeted cytokine for cancer immunotherapy
Rajbharan Yadav, Suzanne Schubbert, Patrick G. Holder, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Rajbharan Yadav, Suzanne Schubbert, Patrick G. Holder, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
The Immunoregulatory Effect of Aconite Treatment on H22 Tumor-Bearing Mice via Modulating Adaptive Immunity and Natural Killer-Related Immunity
Huan Wang, Xiu zhong Qi, Wentao Jia, et al.
Evidence-based Complementary and Alternative Medicine (2023) Vol. 2023, pp. 1-10
Open Access | Times Cited: 2
Huan Wang, Xiu zhong Qi, Wentao Jia, et al.
Evidence-based Complementary and Alternative Medicine (2023) Vol. 2023, pp. 1-10
Open Access | Times Cited: 2
Role of interleukins in acute myeloid leukemia
Yin Wang, Xiao Jun Tang, Yu Zhu, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2023) Vol. 64, Iss. 8, pp. 1400-1413
Closed Access | Times Cited: 2
Yin Wang, Xiao Jun Tang, Yu Zhu, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2023) Vol. 64, Iss. 8, pp. 1400-1413
Closed Access | Times Cited: 2
